Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Investigational eIF2B activator DNL343 modulates the integrated stress response in preclinical models of TDP-43 pathology and individuals with ALS in a randomized clinical trial.
Journal: Nature communications
Published: March 31, 2025
Alterations in Lysosomal, Glial and Neurodegenerative Biomarkers in Patients with Sporadic and Genetic Forms of Frontotemporal Dementia.
Journal: bioRxiv : the preprint server for biology
Published: February 26, 2024
Episodic Memory Loss: When Alzheimer's Disease Is Not the Answer.
Journal: Journal of Alzheimer's disease reports
Published: January 21, 2024
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo-controlled, double-blind phase I/Ib studies in healthy subjects and patients.
Journal: Clinical and translational science
Published: March 04, 2022
Open-Label Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy.
Open-Label Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy.
Journal: Movement disorders clinical practice
Published: January 14, 2020
Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: A Randomized Clinical Trial.
Journal: JAMA neurology
Published: November 12, 2019
Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer's disease.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: November 02, 2019
Promoting tau secretion and propagation by hyperactive p300/CBP via autophagy-lysosomal pathway in tauopathy.
Journal: Molecular neurodegeneration
Published: August 21, 2019
Tau PET and multimodal brain imaging in patients at risk for chronic traumatic encephalopathy.
Journal: NeuroImage. Clinical
Published: May 06, 2019
Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders.
Journal: JAMA
Published: October 17, 2018
Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET.
Journal: Science translational medicine
Published: August 03, 2018
18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes.
Journal: Alzheimer's research & therapy
Published: July 02, 2018
Last Updated: 09/26/2026